SI-BONE Analyst Ratings
Positive Outlook for SI-Bone: Robust Revenue Growth and Strategic Advances Reinforce Buy Rating
Morgan Stanley Trims Price Target on SI-Bone to $25 From $26, Keeps Overweight Rating
SI-BONE Analyst Ratings
SI-Bone's Strong Start and Revenue Growth Potential Affirm Buy Rating
JMP Securities Reaffirms Their Buy Rating on SI-Bone (SIBN)
Piper Sandler Keeps Their Buy Rating on SI-Bone (SIBN)
Analysts' Opinions Are Mixed on These Healthcare Stocks: SI-Bone (SIBN), Conmed (CNMD) and Chemed (CHE)
Truist Financial Sticks to Their Buy Rating for SI-Bone (SIBN)
SI-BONE Analyst Ratings
SI-Bone's Favorable Outlook and Buy Rating Amidst Stable Medical Coverage and Growth Prospects
SI-BONE Analyst Ratings
Buy Rating Affirmed for SI-Bone on Expansion and Market Growth Strategies
SI-BONE Analyst Ratings
SI-Bone's Strong Outperformance and Promising Outlook Secure Buy Rating
Buy Rating for SI-Bone Bolstered by Strong Financials and Market Growth Potential
SI-Bone's Strong Financial Performance and Growth Prospects Reinforce Buy Rating
SI-BONE Analyst Ratings
Truist Securities Raises SI-Bone Price Target to $25 From $22, Maintains Buy Rating
SI-Bone: Strong Fundamentals and Impending Profitability Underpin Buy Rating